Suzhou Boten has received CNY 520 million in series B round of funding on August 21, 2022. The transaction included participation from Hillhouse Investment Management, Ltd., Guotou China Merchant Investment Management Co., Ltd. through its fund, Advanced Manufacturing Industrial Investment Fund Phase II (Limited Partnership), Huimei Capital, Yuemin Investment, Shanghai Chuangfeng Medico Private Equity Fund, Huashan Ruilian Fund Management Co., Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., China Merchants Capital Investment Co., Ltd., China Merchants Securities Co., Ltd. and other investors.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.51 CNY | -1.14% | -1.87% | -10.07% |
Apr. 18 | China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy | MT |
Apr. 17 | Fosun Pharma Unit’s New Drug Application for CMV, HSV Drug Accepted by Chinese Regulator | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.07% | 7.48B | |
+24.60% | 672B | |
+24.08% | 550B | |
-5.63% | 351B | |
+15.37% | 317B | |
+7.38% | 292B | |
+3.26% | 211B | |
+0.78% | 203B | |
-9.69% | 144B | |
-6.63% | 141B |
- Stock Market
- Equities
- 600196 Stock
- News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Suzhou Boten announced that it has received CNY 520 million in funding from a group of investors